Results 161 to 170 of about 9,765 (234)

Protein tyrosine kinase Src suppresses hepatitis C virus particle release through regulation of Ndrg1. [PDF]

J Biol Chem
Fu L, Takeuchi K, Chihara K, Feng W, Sada K.   +4 more
europepmc   +1 more source

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. [PDF]

Antimicrob Agents Chemother, 2016
Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.   +11 more
europepmc   +1 more source

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019-2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment. [PDF]

J Clin Transl Hepatol
Xiong H, Pan S, Zhou C, Shi H, Xie Y, Guo J.   +5 more
europepmc   +1 more source

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. [PDF]

Antimicrob Agents Chemother, 2013
Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H.   +7 more
europepmc   +1 more source

A Bibliometric Analysis of the HCV Drug-Resistant Majority and Minority Variants. [PDF]

Int J Environ Res Public Health
Immanuel OM, Fabiyi OT, Oshakbayev KP, Abuova G, Konysbekova A, Vattipally SB, Ali S, Abidi SH.   +7 more
europepmc   +1 more source

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants. [PDF]

Clin Pharmacol Drug Dev
Zhou XJ, Morelli G, Montrond M, Lynch S, Pietropaolo K, Belanger B, Horga A, Hammond J.   +7 more
europepmc   +1 more source

Development of a Norway Rat Hepacivirus Reporter for High-Throughput Quantification of Neutralising Antibodies

Kennedy MJ, Wolfisberg R, Thorselius CE, Collignon L, Lundsgaard EA, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

2025 KASL clinical practice guidelines for management of hepatitis C. [PDF]

Clin Mol Hepatol
Jang ES, Heo NY, Jeong JY, Park JG, Song DS, Cho EJ, Lee CH, Lee JS, Yoon JH, Han SK, Jung YK, Korean Association for the Study of the Liver (KASL).   +11 more
europepmc   +1 more source

Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. [PDF]

Antimicrob Agents Chemother, 2012
Pelosi LA, Voss S, Liu M, Gao M, Lemm JA.   +4 more
europepmc   +1 more source